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Abstract: Natural killer (NK) cell therapy is one of the most promising treatments for Glioblastoma
Multiforme (GBM). However, this emerging technology is limited by the availability of sufficient numbers
of fully functional cells. Here, we investigated the efficacy of NK cells that were expanded and treated by
interleukin-2 (IL-2) and heat shock protein 70 (HSP70), both in vitro and in vivo. Proliferation and cytotoxicity
assays were used to assess the functionality of NK cells in vitro, after which treated and naïve NK cells were
administrated intracranially and systemically to compare the potential antitumor activities in our in vivo rat
GBM models. In vitro assays provided strong evidence of NK cell efficacy against C6 tumor cells. In vivo
tracking of NK cells showed efficient homing around and within the tumor site. Furthermore, significant
amelioration of the tumor in rats treated with HSP70/Il-2-treated NK cells as compared to those subjected to
nontreated NK cells, as confirmed by MRI, proved the efficacy of adoptive NK cell therapy. Moreover, results
obtained with systemic injection confirmed migration of activated NK cells over the blood brain barrier and
subsequent targeting of GBM tumor cells. Our data suggest that administration of HSP70/Il-2-treated NK
cells may be a promising therapeutic approach to be considered in the treatment of GBM.
Keywords: glioblastoma multiforme; rat model; NK cell therapy; MRI cell tracking; fluorescent cell
tracking; blood brain barrier
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1. Introduction
Glioblastoma Multiforme (GBM) is among the most aggressive and lethal malignancies in
humans [1]; it is a devastating brain disease, which typically results in mortality within 15 months
postdiagnosis due to elevated intracranial pressure and interruption of normal functioning of brain
tissues [2–4]. In addition, GBM grows fast and can spread quickly [5–7]. Localization of the tumor in
the brain tends to aggravate its very aggressive nature, as it is out of the reach of the immune system; at
the same time, brain cells have limited capacity to repair themselves [1,8]. Furthermore, leakage of the
tumor capillaries causes fluid accumulation around the tumor and contributes to the aforementioned
increase in intracranial pressure [2,8,9]. Current mainstay therapy for newly diagnosed GBM patients
consists of a maximal resection within the safety limits; however, the tumor is usually infiltrative and
complete resection is typically impossible, and resection must therefore be followed by radio- and
chemotherapy [3,10]. Although tumors may respond to this approach, the likelihood of recurrence
is extremely high due to the stemness property of this malignancy. Glioblastoma stem cells (GSCs),
which constitute a small subpopulation of GBM cells with self-renewing and tumorigenic properties,
contribute to disease initiation, its subsequent therapeutic resistance, and also have the potential ability
to reconstitute the tumor after treatment [11,12]. Moreover, tumor heterogeneity, tumor location in a
region where it is out of range of immune system control, and rapid tumor relapse represent additional
main challenges complicating the treatment of GBM [10,13].
NK cells appear to be the most promising innate immune components when considering immune
cell-based therapy treatment of GBM and other cancers, as they can recognize and kill tumor cells
without any prior priming with tumor-specific antigens [14]. Aside from cytolysis, NK cells produce
an array of cytokines, such as tumour necrosis factor (TNF) and interferons, which orchestrate immune
responses [15]. Importantly, it has been postulated that NK cells target cancer stem cells [16]; however,
the inadequate number and inactivity of NK cells at the tumor site are major concerns. To address
these issues, a number of attempts have been made, most of which by manipulating the receptors
on NK cells, via blocking inhibitory or activating stimulatory receptors (which both result in a net
increase in the release of specific cytokines that suppress NK cell tolerance beyond expansion), or by
engineering chimeric antigen receptors (CARs) to target tumor proteins [17,18].
Heat shock protein 70 (HSP70) is a 70 kilo Dalton (KD) chaperone protein, which is overexpressed in a
number of tumor cells in various cancers, including GBM [19–21]. It provides a cytoprotective role and
leads to inhibition of apoptosis in stressed cells. Elevation of HSP70 in cancer cells may be responsible for
tumor progression by providing resistance to radio- and chemotherapy [22,23], and subsequent post-therapy
survival [20,24,25]. Interestingly, it also serves as a target protein for activated NK cells [21,22,26,27],
which recognize HSP70 as a tumor marker [26,28]. NK cells bind to HSP70 through the killer cell lectin-like
receptor D1 (KLRD1), resulting in granzyme B release and tumor cytolysis [22,29].
In the present study, we have investigated the immunophenotype and proliferative capacity of
IL-2/IL-15 cytokine-treated NK cells and their reactivity against green fluorescent protein (GFP)-labeled
C6 cells in vitro. Subsequently, the potential cytolytic antitumor effects of IL-2/HSP70-treated NK cells
were assessed in vivo in our rat models of GBM.
2. Results
2.1. Ex Vivo Expansion and Immunophenotyping of NK Cells
In order to expand NK cells, freshly isolated CD3−CD161+ cells were cultured in the presence of
cytokines (IL-2+IL-15) and K562 feeder cells or IL-2+IL-15 alone. The resulting cells were expanded for
over 16 days. Expanded NK cells exhibited round shape morphology with clonal growth (red arrow)
under both culture conditions (Figure S1A). In the presence of cytokines or cytokines/feeder cells, cells
expanded 30- to 37.6-fold, respectively. The growth rate and yield of the cells were similar without
noticeable differences between cytokine- and cytokine/feeder-treated cells for up to 16 days (Figure S1B).
Expanded cells were evaluated for the expression of NK cell surface markers; more than 90% of the
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population was CD3 negative and CD161 positive (supplementary material, Figure S2). Proliferation
of cytokine-treated NK cells was also examined in co-culture with GBM tumor cells at different ratios.
We found that carboxy fluorescein succinimidyl ester (CFSE)-labeled NK cells demonstrated a significantly
higher proliferation rate at a 1:3 Target (T):Effector (E) cell ratio as compared to other ratios studied (Figure
S3A,B). It seemed that NK cells had high demand for nutrients to generate ATP, and biosynthesis of
cellular macromolecules including lipids, proteins and nucleic acids. Since the level of essential nutrients
such as glucose, fatty acid and glutamine were limited in culture media, this might cause a competition
between effector cells. It could be an explanation for lower cytotoxicity and proliferation of NK cells [30].
2.2. In Vitro Cytotoxic Activity of Cytokine-Treated NK Cells
To assess cytotoxic activity of cytokine-treated NK cells, we co-cultured IL-2/IL-15-treated NK cells
(E) and green fluorescent protein (GFP)-labeled GBM tumor cells (T) at different ratios. Flow cytometry
analysis was performed through gating the GFP-positive/propidium iodide (PI)-positive cells as
necrotic glioblastoma cells (Figure S4A). Our results indicate that NK cells were cytotoxic towards
GBM tumor cells. We also assessed the co-culture behavior of different ratios of T:E cells (1:1, 1:3, 1:5)
(Figure S4B). We found that there were no significant differences between different ratios. Interestingly,
lactate dehydrogenase (LDH) activity in the supernatant, a cell lysis and necrosis biomarker, increased
significantly as a consequence of co-culture with NK cells in comparison with the negative control (C6).
However, no significant differences in the level of cytotoxicity were observed between the various
concentrations T:E-ratios of NK cells studied. Overall, these results demonstrate the cytotoxicity of
expanded NK cells (Figure S4C).
2.3. Bio-Distribution of Intracranially and Systemically Injected NK Cells in a Rat GBMModel
Fluorescence in vivo imaging was used to evaluate the bio-distribution of cytokine-treated NK cells,
2 days after systemic injection in our induced GBM rat model. Paul Karl Horan (PKH-26)-labeled and
IL-2/HSP70-treated NK cells demonstrated a potent ability to target GFP-expressing GBM cells within the
tumor. Two days after injection, we observed the infiltration of IL-2/HSP70-treated NK cells around the
GBM cells. Acquired images revealed a reduction in GBM tumor burden on day 8 (Figure 1). Figure 2A
depicts the whole image of thick slices of brain tissue (350 µm) with tumor and NK cell injection sites in
4′,6-diamidino-2-phenylindole (DAPI)-stained sections as captured by fluorescent microscopy. For further
confirmation, the animals were sacrificed, and brain tissues were delipidated to be optically transparent. 3D
confocal imaging of clarified brain slices revealed precise targeting of GFP-expressing GBM tumor cells
by PKH26-labeled NK cells (Figure 2B). Reconstructed images using Imaris software also confirmed the
presence of NK cells in the proximity of GBM tumor cells (Figure 2C). These results demonstrate that NK
cells can deeply penetrate into the GBM tumor and launch a pitched battle.
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Figure 1. Bio-distribution of NK cells in the rat model of induced GBM; live imaging. Bio-distribution 
of PKH-26-labeled NK cells 2 days after intravenous injection in our GFP-labeled GBM tumor induced 
model. (A) GFP-labeled GBM cells were found at day 0 (tumor establishment, white dotted frame). 
(B) Fluorescence imaging on day 2 shows the localization of PKH-labeled NK cells around GFP-
labeled tumor cells (white dotted frame). (C) A reduction of fluorescence intensity of GFP-labeled 
GBM cells was evident 8 days post injection, indicating the effectiveness of the introduced NK cells 
(white dotted frame). 
Figure 2. NK cell homing and interaction with tumor cells. (A) Representative image of a thick brain 
section stained with DAPI to identify the tumor and NK cell interaction zone. (B) 3-Dimentional 
confocal imaging showing deep penetration of PKH-labeled NK cells into the tumor (GFP-labeled 
tumor cells). (C) An overview of NK cells (red spheres) and tumor cells (green spheres) as 
reconstructed by Imaris software. 
Systemic injection of NK cells was an approach used to assess whether treated NK cells were 
able to target tumor cells, even after traveling the longest distance from tail to head. Our data showed 
that the infiltration of NK cells inside the tumor tissue may correspond to their anti-tumor activity 
after systemic injection. Magnetic resonance imaging (MRI) molecular tracing was applied to 
determine homing of NK cells and their interaction with tumor cells. Superparamagnetic iron oxide 
(SPIO)-labeled NK cells were intracranially injected and MRI was performed to investigate NK cell 
localization; the details of this imaging protocol are described in our previous work [5]. MRI results 
demonstrated the infiltration of SPIO-labeled NK cells both around and inside the tumor area 2 days 
after intracranial injection. Furthermore, SPIO-labeled NK cells exhibited anti-GBM activity 8 days 
post intracranial injection (Figure 3). 
Figure 1. Bio-distribution of NK cells in the rat model of induced GBM; live imaging. Bio-distribution
of PKH-26-labeled NK cells 2 days after intravenous injection in our GFP-labeled GBM tumor induced
model. (A) GFP-labeled GBM cells were found at day 0 (tumor establishment, white dotted frame).
(B) Fluorescence imaging on day 2 shows the localization f PKH-labeled N c lls around GFP-labeled
tumor cells (white dotted frame). (C) A reduction of fluorescence intensity of GFP-labeled GBM cells was
evident 8 days post injection, indicating the effectiveness of the introduced NK cells (white dotted frame).
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Systemic injection of NK cells was an approach used to assess whether treated NK cells were able
to target tumor cells, even after traveling the longest distance from tail to head. Our data showed that
the infiltration of NK cells inside the tumor tissue may correspond to their anti-tumor activity after
systemic injection. Magnetic resonance imaging (MRI) molecular tracing was applied to determine
homing of NK cells and their interaction with tumor cells. Superparamagnetic iron oxide (SPIO)-labeled
NK cells were intracranially injected and MRI was performed to investigate NK cell localization; the
details of this imaging protocol are described in our previous work [5]. MRI results demonstrated the
infiltration of SPIO-labeled NK cells both around and inside the tumor area 2 days after intracranial
injection. Furthermore, SPIO-labeled NK cells exhibited anti-GBM activity 8 days post intracranial
injection (Figure 3).
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Figure 2. NK cell homing and interaction with tumor cells. (A) Representative image of a thick brain
section stained with DAPI to identify the tumor and NK cell interaction zone. (B) 3-Dimentional
confocal imaging showing deep penetration of PKH-labeled NK cells into the tumor (GFP-labeled
tumor cells). (C) An overview of NK cells (red spheres) and tumor cells (green spheres) as reconstructed
by Imaris software.
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Figure 3. NK cell tracing by MRI. MR imaging of SPIO-labeled NK cells 2 and 8 days after intracranial 
injection. Yellow ellipses point at approximate location of the injected GBM cells. 
2.4. In Vivo Functional Anti-GBM Activity of Rat NK Cells 
To evaluate tumor establishment after C6 injection, all groups were observed for any changes in 
behavior, appetite, and body weight; MRI was performed to determine the tumor area 8 days after 
GBM tumor cell injection. Tumor mass, with necrotic area and edema as hallmark features of GBM, 
was observed in the MRI images. 
In order to investigate the anti-tumor effect of NK cells, GBM-induced animals were divided 
into two trial groups: intracranial and systemic cell therapy models, which received IL-2/HSP70-
treated NK cells or nontreated NK cells. MRI results revealed that as compared to the initial tumor 
size before treatment, tumor size was significantly reduced in the group intracranially injected with 
IL-2/HSP70-treated NK cells. However, no significant changes in tumor volume were observed after 
injection of nontreated NK cells (Figure 4A). The data showed a significant reduction in tumor size 
in animals exposed to treated NK cells versus those injected with nontreated NK cells. Furthermore, 
the survival rate was markedly improved in animals that had received treated NK cells compared to 
those subjected to nontreated NK cells. Animals treated with treated NK cells were alive for at least 
90 days. Details of the in vivo anti-GBM effects of NK cells in the intracranial group are provided in 
Figure 4B. 
 
Figure 3. NK cell tracing by MRI. MR imaging of SPIO-labeled NK cells 2 and 8 days after intracranial
injection. Yellow ellipses point at approximate location of the injected GBM cells.
2.4. In Vivo Functional Anti-GBM Activity of Rat NK Cells
To evaluate tumor establishment after C6 injection, all groups were observed for any changes in
behavior, appetite, and body weight; MRI was performed to determine the tumor area 8 days after
GBM tumor cell injection. Tumor mass, with necrotic area and edema as hallmark features of GBM,
was observed in the MRI images.
In order to investigate the anti-tumor effect of NK cells, GBM-induced animals were divided into
two trial groups: intracranial and systemic cell therapy models, which received IL-2/HSP70-treated
NK cells or nontreated NK cells. MRI results revealed that as compared to the initial tumor size
before treatment, tumor size was significantly reduced in the group intracranially injected with
IL-2/HSP70-treated NK cells. However, no significant changes in tumor volume were observed
after injection of nontreated NK cells (Figure 4A). The data showed a significant reduction in
tumor size in animals exposed to treated NK cells versus those injected with nontreated NK cells.
Furthermore, the survival rate was markedly improved in animals that had received treated NK cells
compared to those subjected to nontreated NK cells. Animals treated with treated NK cells were alive
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for at least 90 days. Details of the in vivo anti-GBM effects of NK cells in the intracranial group are
provided in Figure 4B.
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Figure 4. MRI results of intracranial injection of NK cells in the rat model of induced GBM. (A) T2-
weighted MR Images of GBM tumor-bearing rats show tumor shrinkage over time to nearly 
undetectable size at day 8, after injection with HSP70/IL-2-treated NK cells (panels on the left). No 
robust effects of injection with nontreated NK cells were observed (panels on the right) yellow dotted 
circles show tumor zones. (B) Graph depicting tumor volume shrinkage at day 8 in rats intracranially 
injected with treated NK cells versus nontreated NK cells (** p-value: 0.0319). Tumor size in missed 
(dead) cases was considered as unchanged. 
MRI results showed similar antitumor activity, with markedly high tumor shrinkage and 
survival rate, of systemically administered treated NK cells (Figure 5A,B). Systemic injection of 
nontreated NK cells led to early death of the experimental animals. 
 
Figure 4. MRI results of intracranial injection of NK cells in the rat model of induced GBM.
(A) T2-weighted MR Images of GBM tumor-bearing rats show tumor shrinkage over time to nearly
undetectable size at day 8, after injection with HSP70/IL-2-treated NK cells (panels on the left). No robust
effects of injection with nontreated NK cells were observed (panels on the right) yellow dotted circles
show tumor zones. (B) Graph depicting tumor volume shrinkage at day 8 in rats intracranially injected
with treated NK cells versus nontreated NK cells (** p-value: 0.0319). Tumor size in missed (dead) cases
was consi ered as unchanged.
MRI results showed similar antitumor activity, with markedly high tumor sh inkage nd survival
rate, of systemically administered treated NK cells (Figure 5A,B). Systemic injection of on reated NK
cells led to early death of the experimental animals.
Histopathological analysis of H&E-stained sections showed that all animals in the sham group
developed a GBM tumor, characterized by pseudopalisading necrosis, microvascular hyperplasia,
hypercellularity and pyknotic cells (Figure 6A). Importantly, animals in the systemic and intracranial
groups that had received treated NK cells showed marked reduction of necrosis and microvascular
hyperplasia 30 days after treatment as compared to animals in the sham group (Figure 6B,C).
As presented, we also observed infiltration of lymphocytes in both groups injected with treated
NK cells [31,32].
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injection of IL-2/HSP70-treated NK cells represent smooth brain surface, no lesions are identified. 
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with atypia, brisk mitosis and karyorrhexis: GBM in the sham group (right picture). (B,a) Gross
morphology of the rat brain and cerebellum of the group that received intracranial injection of
IL-2/HSP70-treated NK cells represent smooth brain surface, no lesions are identified. (B,b) Images
of the experimental group that received intracranial injection of IL-2/HSP70-treated NK cells indicate
normal cellularity, normal glial cells, neurons and astrocytes in the neuropil background as compared
to GBM control, Figure 6A,b. No signs of necrosis, inflammation or desmoplasia were observed
(30 days post injection). (C,a) Gross morphology of the group that received systemic injection of
IL-2/HSP70-treated NK cells, the rat brain and cerebellum represent smooth brain surface, no lesions are
identified. (C,b) Images of the experimental group that received systemic injection of IL-2/HSP70-treated
NK cells indicate normal glial cells, neurons and astrocytes in the neuropil background with mild
lymphocytic infiltration, and few visible capillaries as compared to GBM control, Figure 6A,b (30 days
post injection). (D,a) Gross morphology of the rat brain and cerebellum of the group that received
intracranial injection of nontreated NK cells. Smooth brain surface. No lesions are identified. (D,b)
Images of the experimental group that received intracranial injection of nontreated NK cells showed
normal glial cells, neurons and few atypical astrocytes with focal lymphocytic infiltration in a neuropil
background compared to GBM positive control, Figure 6A,b (30 days post injection).
3. Discussion
Extensive genetic and cellular diversities render GBM difficult to treat and eradicate. In spite
of various modalities of treatments, overall survival has only modestly increased over the last 30
years [3,8,33,34]. Immune cell therapy has emerged as a promising tool to tackle GBM [35–38].
Several studies demonstrated immune cell infiltration in the brain of patients with malignant glioma,
although it was previously considered as an immune-privileged organ [39,40]. However, tumor-derived
factors suppressed immune responses of these cells [41]. Previous studies showed that tumor-residing
glioma cells regulate the immune response through recruitment of immune-suppressive cells, which
represents a challenge in the development of cell immunotherapies [42].
NK cells have been considered as an effective treatment modality for cancer treatment for over 50
years; however, efficacy has been limited due to the availability of relatively small numbers and lack of
sufficient activation in the vicinity of the tumor [43]. Such concerns are even more important in GBM
due to the unique localization of the tumor, which limits trafficking of NK cells over the blood-brain
barrier (BBB) from the blood into the brain [44]. In the first step of our study, evaluation of NK cell
cytotoxicity and proliferation demonstrates the NK cell effectiveness against GBM cells (C6) in vitro.
Although the NK cell/C6 cell co-culturing conditions are not fully identical to the environment in vivo,
this in vitro setup serves as an optimally controllable system to closely predict the effects of NK cells
on tumor cells in vivo.
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Results of the CFSE proliferation assay proved rapid expansion of NK cells in co-culture with the
GBM cell line. Moreover, in vitro cytotoxicity assessment indicated the lysis potential on C6 tumor
cells. The PI incorporation test and LDH release assay were used to determine the cytotoxic effects [40];
these methods were chosen over assessing chromium-51 release out of ecologic considerations. For
the PI incorporation assay, we co-cultured NK cells with GFP-labeled C6 cells and assessed the rate
of C6 cell death by selecting GFP/PI positive cells among total GFP-expressing cells, using flow
cytometry. This protocol is cost-effective and, unlike the chromium-51 release assay, does not produce
hazardous waste. Flow cytometry data indicated a cytotoxicity of stimulated NK cells on C6 cells,
which was more pronounced with a higher number of NK cells present (dose-dependent results).
The LDH assay further confirmed the cytotoxic capacity of activated NK cells, albeit with an apparent
lower sensitivity, as significant differences between various doses of NK cells could not be identified,
suggesting dose-dependency is subtle and might only be detected with more sensitive approaches.
Based on the results obtained from our in vitro experiments, we evaluated the antitumor effects of
ex vivo-expanded and HSP70/IL-2-treated NK cells in our GBM rat models and compared two different
routes of administration of NK cells (systemic versus intracranial).
In the in vivo part of our studies, we aimed to address key questions such as (i) is HSP70\IL-2
treatment sufficient to facilitate recruitment of NK cells into the tumor site? and (ii) is this stimulation
robust enough to enable sufficient numbers of activated NK cells cross the blood-brain barrier and
trigger the antitumor activity? In our previous study, we investigated the similarities between human
GBM and the C6-induced GBM rat model [5]. By applying bioinformatic tools, MRI and histopathology
assessments, we established that this model closely resembles the human condition, to an extent that
it could be exploited in preclinical immune cell therapy assessment. Our current data demonstrate
that IL-2/HSP70 can effectively stimulate NK cells, enhancing their targeting, homing and cytolytic
properties. We implemented several different protocols: (a) live in vivo imaging, which showed the
accumulation of NK cells around the tumor microenvironment, and tumor shrinkage 8 days after NK
cell injection; (b) 3D imaging by confocal microscopy of thick brain slices, which confirmed tumor
targeting by PKH-26-labeled NK cells. In addition, deep penetration of PKH-26-labeled NK cells into
the GBM tumor was evident, supporting the ‘death kiss’ hypothesis, which is a symbolic expression
for NK cell-induced cytolysis, as previously described [45,46]; and (c) MRI tracing of SPIO-labeled NK
cells, which demonstrated tumor targeting after 48 h and tumor shrinkage 8 days after SPIO-labeled
NK cell therapy. To the best of our knowledge, this is the first preclinical study showing the tug of war
between NK and tumor cells on a cellular and molecular level.
Finally, the antitumor activities of naïve nontreated and IL-2/HSP70-treated NK cells were evaluated
and compared by MRI, showing effectiveness of treated NK cells manifested by tumor shrinkage,
both after intracranial and systemic injection. Of note, the tumor size in rats treated with systemically
injected, nontreated NK cells could not be properly evaluated due to the early, tumor-related death
of those animals. Intravenous injection of IL-2/HSP70-treated NK cells, which targeted GBM cells in
the brain, did further confirm the effectiveness of activated NK cells, which exhibited specific homing
properties, accumulating in the brain, and reaching the tumor cells. It is noteworthy to emphasize that,
compared to naive nontreated NK cells, a short-term treatment with HSP70/IL-2-activated NK-cells
results in significant tumor shrinkage and survival.
A small number of studies exist in which attempts were made to enhance the cytotoxic effect of NK
cells towards tumor cells. For instance, the utilization of a programmed cell death protein (PD-1) blocker
in a multiple myeloma model, resulted in increased NK cytotoxicity markers and therapeutic efficacy
toward this malignancy [47]. A follow-up study demonstrated the cytotoxicity enhancement of TKD
(antigenic component of HP70)/IL-2-activated NK cells by PD-1 blocker stimulation, which resulted
in local tumor control in immunodeficient and/or immunocompetent mice, in GBM and lung cancer
models [48]. However, the expression of PD-1 on GBM cells is highly questionable [49]. On the other
hand, GBM represents an immunosuppressive microenvironment characterized by low immunogenic
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responses. Therefore, whether these results are related to PD-1, TKD/IL-2 or a synergistic or additive
effect of both stimulation methods remains to be elucidated.
The results of our in vivo studies provide, at least to some extent, answers to the aforementioned
questions, since the anatomical size of the rat is large enough to evaluate the tumor after immune
cell therapy. Furthermore, many genetic and signaling pathway perturbations, and key pathological
features that can be evaluated by MRI, are common between autochthonous human GBM and induced
rat GBM according to our previous studies; therefore, we are confident that data generated by our
experimental in vitro and in vivo systems are of clinical importance and open the door for further
translational research.
4. Material and Methods
4.1. Cell Line
The rat glioblastoma cell line (C6) was purchased from the National Cell Bank of Iran (NCBI),
Pasteur institute, C575. Cells were cultured in DMEM F-12, supplemented with 2.5% fetal bovine
serum and 12.5% horse serum.
Cells were observed daily and, after formation of a confluent monolayer, passaged serially.
Expanded in such way, cells were divided into two groups: (1) cells that were frozen for future use,
and (2) cells that were labelled with GFP for tracing experiments in the (GBM) rat brain, as previously
described [50].
4.2. Natural Killer Cell Isolation, Expansion, and Stimulation
All animal protocols have been approved by the Review Board and Institutional Ethics Committee
of the Royan Institute (IR.ACERCR.Royan.REC.1395.59 21/06/2016). Mononuclear cells (MNCs) were
obtained from rat spleens, followed by density separation using Lympholyte® Cell Separation density
gradient centrifugation media (Cedarlane, Canada). These MNCs were subjected to FACS positive
selection of NK cells. Next, NK cells were isolated by positive selection of CD161+CD3- cells using
FACS. Briefly, MNCs were stained using phycoerythrin (PE)-conjugated anti-CD161, and fluorescein
isothiocyanate (FITC)-conjugated anti-CD3, according to the manufacturer’s protocol.
To obtain optimal NK cell expansion, we implemented two different protocols and compared their
results. Isolated NK cells were cultivated in complete RPMI 1640 medium, with different enrichment
approaches: the first group was supplemented with K562 as feeder cells and IL-2 (1000 IU/mL) and
IL-15 (100 IU/mL), the second group was supplemented with cytokines alone. Both groups were
incubated in a humidified incubator (5% CO2 at 37 ◦C).
In accordance with the previously published procedure, NK cells were activated by adding HSP70
(2 µg/mL) and IL-2 (100 IU/mL) to the culture medium, and further incubated under standard cell
culture conditions for four days [29].
4.3. In Vitro Proliferation Assay, NK Cells In Co-Culture with GBM Cells
To probe NK cell proliferation in the vicinity of the C6 cell line, isolated NK cells were labeled
with CFSE through a previously established method with a few modifications [51,52]. Briefly, NK cells
were dyed with 1 µL CFSE and cultured in complete RPMI 1640 medium, in a humidified incubator
(5% CO2, at 37 ◦C) for 72 h.
4.4. NK Cells in Vitro Cytotoxicity Assays
The cytotoxic effects of NK cells on C6 tumor cells were determined in a co-culture of GFP-labeled
C6 (target, T) cells and NK (effector, E) cells; T:E: ratios of 1:1, 1:3, and 1:5 were studied. After 24 h of
incubation, the supernatant was collected for an LDH assay, as a necrosis marker in cell culture
medium [53], which was performed using a kinetic method, and cells were analyzed using a
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FACS-CANTO flow cytometer. To determine the relative extent of apoptotic and necrotic cell
death, propidium iodide (PI; 1 µg/mL) was added.
4.5. Animal Studies
Glioblastoma Rat Modeling
Animal studies were performed using a total of 14 male rats with body weights of 230–250 g.
All animal experiments were approved by the review board and institutional ethics committee of the
Royan Institute (IR.ACERCR.Royan.REC.1395.59 21/06/2016). Selected animals were anesthetized
with ketamine/xylazine (55/11) mg/kg by peritoneal injection, and subjected to stereotaxic surgery,
according to our previously published protocol [5]. Briefly, animals were divided into two groups:
the experimental group receiving C6 glioblastoma cells, and a sham-exposed group receiving culture
media. Any changes in movement ability and bloody discharge of the eyes were noted as tumor
implantation signs. Tumor establishment and treatment follow-up was assessed by MRI [5].
4.6. NK Cells Bio-Distribution Assays
We implemented three different procedures for in vivo tracking of NK cells:
(a) MRI molecular tracing: NK cells were labeled with commercially available (SPIO) nanoparticles
at a concentration of 100 µg/mL with protamine sulfate as a transfecting agent at a final concentration
of 45 µg/mL. The mixture was added to FBS/l-glutamine free culture media containing NK cells
for 2 h. Subsequently, we added 1% l-glutamine and 10% FBS and incubated for 48 h. After this
period, these labeled cells were washed twice with sterile PBS and introduced to GBM-induced rats by
intracranial injection, followed by tracking by MRI [54,55]. MRI was performed 48 h post injection
with SPIO-labeled NK cells using a 3.0 T Prisma, Siemens apparatus equipped with a 75-rat coil. T2
mapping with the acquisition of T1- and T2-weighted anatomical images was performed.
(b) Live in vivo fluorescent imaging: (PKH)-26 staining (emitted at 567 nm) was utilized in an
additional attempt to trace NK cells and identify their potential interactions with tumor cells. For this
purpose, NK cells were centrifuged for 5 min at 400× g, followed by suspension of the pellet in 1 mL
diluent C to prevent direct contact of cells with dye. In a separate vial, a concentration of 4×10−6
mol/L was prepared by diluting 4 µL PKH-26 red fluorescent dye in 1 mL diluent C, prior to cell
labeling. Suspended NK cells were mixed with diluted PKH-26 dye and incubated for 5 min at room
temperature, gently inverted to disperse, and finally washed with 1% BSA PBS to stop the staining
process. These cells were used for systemic injection. An additional batch of tumor cells, planned for
implantation, were transfected with GFP (emitted at 509 nm), which allowed us to monitor them by
detecting two distinct wavelengths using a Kodak in vivo F series imaging system (New Haven, CT,
USA).
(c) 3-Dimensional brain imaging using fast Free-of-Acrylamide Clearing Tissue (FACT): We utilized
fast Free-of-Acrylamide Clearing Tissue (FACT), which has been recently established [56], as a third
protocol to study NK cells in vivo. Herein, we employed this tissue clearing method to achieve
fluorescent three-dimensional imaging of rat brain tissue. To improve the efficacy, we perfused animals
with normal saline followed by 4% paraformaldehyde prior to decapitation. One mm thick slices of
brain tissue were subjected to clearing by 8% SDS (pH: 7.5) at 37 ◦C for 42 h, to completely delipidate
the brain section. Slices were subsequently washed with PBS for 12 h to remove the excess SDS. To
improve clarity and transparency, brain slices were incubated with sorbitol for 4 h. Next, slices were
subjected to confocal microscopy (Concord, ON, Canada) (Leica; Z size: 330 µm). The Imaris surface
algorithm was applied to create a 3-dimensional reconstruction of GFP-expressing GBM cells and
PKH-labeled NK cells.
Int. J. Mol. Sci. 2020, 21, 2263 12 of 16
4.7. Histopathology Assessments
Animals were sacrificed through perfusion (to achieve proper fixation and preserve brain tissue
from any damage until time of experimentation [57]). Tissues were subjected to paraffin embedding;
subsequently, blocks were sectioned at 5 µm thickness by a microtome. Hematoxylin & Eosin (H&E)
was applied for general histopathological studies.
4.8. Statistics
Statistical analysis was performed using GraphPad Prism software (version 6) and data are
presented as mean ± SD from at least three independent experiments. We utilized one way analysis of
variance (ANOVA) followed by a Tukey (or Holm-Sidak for MRI results) post hoc test to evaluate the
statistical significance of differences between groups. Differences were considered to be statistically
significant when p < 0.05.
5. Exciting Prospects and Existing Questions
Considering our findings on the antitumor effects of HSP70/IL-2-treated NK cells in our in vivo
rat model of induced GBM, we envision translation of this novel treatment approach to tackle GBM in
humans, although there are some ambiguities which remain. Our studies did not directly shed light
on mechanistic processes underpinning NK cell activities. Further, in depth studies are warranted
to identify the exact mechanism that drives NK cell recruitment through the BBB towards the tumor
site. In this respect, two distinct agents appear to be involved: HSP70 and neurotactin (CX3CL1 or
fractalkine) [58–60]. The interactions between neurotactin/fractalkine and HSP70 likely play a key
role in the chemoattraction towards and crossing over the BBB. Regarding our studies, one of the
most important questions remaining is if the activation of HSP70 with IL-2 is of a synergistic or a
central nature. The microenvironment components and their effects on immune cells as well as their
mechanisms of action are other important issues to be addressed. Moreover, it would be valuable to
determine if stimulation of NK cells with HSP70/IL-2 could induce a memory of NK cells to prevent
future tumor recurrence. Taken together, our findings have established that ex vivo HSP70/IL-2
stimulation potently activates NK cells, which enables them to effectively cross the BBB and target
tumor cells in our in vivo rat model of induced GBM.
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